The Muscle Invasive Bladder Cancer (MIBC) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Muscle Invasive Bladder Cancer (MIBC): An Overview
Urothelial Carcinoma starts when cells that make up the urinary bladder become cancerous. Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial. Epithelial tumors with differentiation toward normal urothelium are urothelial/ urinary carcinoma (UC).
From a clinical point of view, urinary bladder cancers are classified as non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), because the invasion of the muscle layer is the major determinant of carrying out a cystectomy.
The majority of UC occurs in males with approximately has two-to-three fold greater incidence as compared to females. UC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin.
Muscle Invasive Bladder Cancer Market Key Facts
-
As per the National Cancer Institute, a high increase in the number of cases of UC with an estimated number of 80,470 newly diagnosed cases and 17,670 deaths were expected in 2019 in the United States.
-
Bladder cancer has also been segregated on the basis of severity of urothelial carcinoma, i.e., non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer at the time of diagnosis. As per Delveinsight, around 50,632 and 21,700 cases for NMIBC and MIBC respectively were occurred in 2017 in the United States.
-
The total incident population of Urothelial Carcinoma in the seven major markets was found to be 243,151 cases in 2017, whereas the total cases of locally advanced/metastatic UC in the 7MM were 96,711 cases in 2017. The diagnosed incident population of UC in the 7MM is expected to increase at a CAGR for the study period, i.e., 2017–2030.
-
Among EU5 countries, Germany had the maximum total cases of locally advanced/metastatic Urothelial Carcinoma with 15,192 cases in 2017.
-
In 2017, the localized, regional and distant cases were estimated to be 32,293, 7072, and 1512, respectively, in Japan.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
Key Benefits of Muscle Invasive Bladder Cancer Market Report
-
The report provides an in-depth analysis of MIBC Market Size and Share till 2030 in the seven major markets.
-
The report will help in developing business strategies by understanding the Muscle Invasive Bladder Cancer (MIBC) Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.
-
It covers MIBC current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
-
The report provides a detailed assessment of the Muscle Invasive Bladder Cancer (MIBC) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Muscle Invasive Bladder Cancer (MIBC) Market
The treatment protocols used for MIBC or Urothelial Carcinoma include chemotherapy, immunotherapy, radiation therapy, target-specific therapy, and surgical treatment. Metastatic urothelial carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancements in the treatment of new immunotherapies, more alternatives are available.
As per DelveInsight, the rising awareness, the introduction of novel drugs, and changing lifestyles are some of the key factors expected to drive the growth of the MIBC market during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Muscle Invasive Bladder Cancer market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the MIBC market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Muscle Invasive Bladder Cancer Epidemiology
The epidemiology section covers insights about the historical and current Muscle Invasive Bladder Cancer patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Muscle Invasive Bladder Cancer market or expected to get launched in the market during the study period. The analysis covers Muscle Invasive Bladder Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the MIBC Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Key companies in the Muscle Invasive Bladder Cancer market include:
-
Merck
-
Bristol-Myers Squibb
-
Genentech
-
AstraZeneca
-
Janssen
-
UroGen Pharma
-
Astellas Pharma
-
Rexahn Pharmaceuticals
-
Immunomedics
-
Nektar Therapeutics
-
Acerta Pharma
-
Infinity Pharma
-
QED Therapeutics
-
Seattle Genetics
And many others.
Muscle Invasive Bladder Cancer Therapies covered in the report includes:
-
Sacituzumab govitecan (IMMU-132)
-
Bempegaldesleukin (NKTR-214)
-
RX-3117
-
ACP-196
-
IPI-549
-
Linrodostat (BMS-986205)
-
Infigratinib
And many others.
Request for Sample @ Muscle Invasive Bladder Cancer (MIBC) Emerging Therapies and Key Companies
Table of Content
1. Key Insights
2. Executive Summary
3. Muscle Invasive Bladder Cancer (MIBC) Competitive Intelligence Analysis
4. Muscle Invasive Bladder Cancer (MIBC) Market Overview at a Glance
5. Muscle Invasive Bladder Cancer (MIBC) Disease Background and Overview
6. Muscle Invasive Bladder Cancer (MIBC) Patient Journey
7. Muscle Invasive Bladder Cancer (MIBC) Epidemiology and Patient Population
8. Muscle Invasive Bladder Cancer (MIBC) Treatment Algorithm, Current Treatment, and Medical Practices
9. Muscle Invasive Bladder Cancer (MIBC) Unmet Needs
10. Key Endpoints of Muscle Invasive Bladder Cancer (MIBC) Treatment
11. Muscle Invasive Bladder Cancer (MIBC) Marketed Products
12. Muscle Invasive Bladder Cancer (MIBC) Emerging Therapies
13. Muscle Invasive Bladder Cancer (MIBC) Seven Major Market Analysis
14. Attribute Analysis
15. Muscle Invasive Bladder Cancer (MIBC) Market Outlook (7 major markets)
16. Muscle Invasive Bladder Cancer (MIBC) Access and Reimbursement Overview
17. KOL Views on the Muscle Invasive Bladder Cancer (MIBC) Market.
18. Muscle Invasive Bladder Cancer (MIBC) Market Drivers
19. Muscle Invasive Bladder Cancer (MIBC) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
Latest Reports By DelveInsight
Malignant Pleural Mesothelioma (MPM) Market
DelveInsight’s Malignant Pleural Mesothelioma (MPM) Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and the historical and forecasted Malignant Pleural Mesothelioma (MPM) epidemiology as well as the market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.
Healthcare Blog by DelveInsight
Bone Metastasis Market Size and Share Analysis
The Bone Metastasis emerging pipeline is currently very limited as only a few prominent players including Exelixis, Actuate Therapeutics, and others are working in the domain. The rising awareness about metastatic bone cancer and the increasing prevalence of the disease offers immense opportunities for other pharma and biotech companies to explore the therapeutics domain. In the coming years, the launch of novel therapies and extensive research and development activities in the domain will accelerate market growth. However, the few diagnostic challenges will hamper the market growth. Read More: Bone Metastasis Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/